ReviewMaterials today. Bio2025
Pathogenesis guided application of nanozymes in the treatment of inflammatory bowel disease.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Multifunctional Cu-doped MnMaterials today. Bio · 2026Article
- Understanding obesity-cancer crosstalk to inform the immunomodulatory roles of anti-obesity nanotherapeutics.Materials today. Bio · 2026Review
- Recent Advances in Nanozymes Toward Diabetic Foot Ulcers.International journal of nanomedicine · 2026Review
- Engineered nanozyme immunomodulator for xerostomia treatment via regulating submandibular salivary gland.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gut that has caused an escalating burden on the global healthcare system in recent years. Researchers have been actively seeking innovative therapeutic strategies to combat this intractable disease. Recent advances in nanozyme technology have opened up new avenues for the development of novel therapeutic strategies for IBD. This review provides a comprehensive overview of the related works in the developments and applications of different nanozymes for IBD therapy. By overviewing the known pathogenesis of IBD and pathogenesis-guided applications of nanozymes in IBD therapy, this review highlights the opportunities for nanozyme-based strategies to address IBD via the underlying mechanisms. This review also examines the current state of nanozyme research in IBD, including the design and application of nanozymes, and discusses the challenges and future directions for this emerging field. In addition, by integrating the understanding of IBD pathogenesis with the development of nanozyme technology, this review aims to stimulate further research to uncover new opportunities for this debilitating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.